4-chloro-5-methylfuro[2,3-d]-pyrimidine | 1321618-96-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃[2,3-d]嘧啶
• 英文名称: 4-chloro-5-methylfuro[2,3-d]-pyrimidine
• 英文别名: 4-Chloro-5-methylfuro[2,3-D]pyrimidine；4-chloro-5-methylfuro[2,3-d]pyrimidine
• CAS: 1321618-96-5
• 化学式: C₇H₅ClN₂O
• 分子量: 168.583
• InChiKey: BEWBKSZFUCZYQP-UHFFFAOYSA-N

物化性质

• 沸点：
  257.6±35.0 °C(Predicted)
• 密度：
  1.393±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  4-chloro-5-methylfuro[2,3-d]-pyrimidine 在 吡啶 、 盐酸 、 tris(bipyridine)ruthenium(II) dichloride hexahydrate 、 三乙胺 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 1,2-二氯乙烷 为溶剂， 反应 98.0h， 生成
  参考文献：
  名称：

  Scaffold-hopping identifies furano[2,3-d]pyrimidine amides as potent Notum inhibitors

  摘要：

  The carboxylesterase Notum is a key negative regulator of the Wnt signaling pathway by mediating the depalmitoleoylation of Wnt proteins. Our objective was to discover potent small molecule inhibitors of Notum suitable for exploring the regulation of Wnt signaling in the central nervous system. Scaffold-hopping from thienopyrimidine acids 1 and 2, supported by X-ray structure determination, identified 3-methylimidazolin-4-one amides 20-24 as potent inhibitors of Notum with activity across three orthogonal assay formats (biochemical, extra-cellular, occupancy). A preferred example 24 demonstrated good stability in mouse microsomes and plasma, and cell permeability in the MDCK-MDR1 assay albeit with modest P-gp mediated efflux. Pharmacokinetic studies with 24 were performed in vivo in mouse with single oral administration of 24 showing good plasma exposure and reasonable CNS penetration. We propose that 24 is a new chemical tool suitable for cellular studies to explore the fundamental biology of Notum.

  DOI：

  10.1016/j.bmcl.2019.126751
• 作为产物：
  描述：

  5-Methylfuro[2,3-d]pyrimidin-4(3H)-one 在 三氯氧磷 作用下， 反应 0.5h， 生成 4-chloro-5-methylfuro[2,3-d]-pyrimidine
  参考文献：
  名称：

  Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold

  摘要：

  A series of thieno[2,3-d]pyrimidines and furo[2,3-d] pyrimidines were synthesized and evaluated for the c-Met inhibition. Thieno[2,3-d]pyrimidine 6b stood out as the most potent showing an IC(50) of 35.7 nM. This compound displayed high inhibitory effect on cell proliferation in BaF3-TPR-Met cells and showed high selectivity for c-Met family against other 14 tested kinases. However, compound 6b was found ineffective in the c-Met-dependent U-87MG human gliobastoma xenograft model that may be relevant to its poor PK profile. (C) 2011 Elsevier Ltd. All rights

  DOI：

  10.1016/j.bmc.2011.05.038

文献信息

• [EN] RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS RADIOMARQUÉS D'IMAGERIE DE MICROTUBULES ET LEURS UTILISATIONS
  申请人：UNIV COLUMBIA

  公开号：WO2019089575A1

  公开（公告）日：2019-05-09

  The present disclosure relates to radiolabeled compounds and methods of uses for diagnosis, monitoring, and treatment of various degenerative neurological disorders, neuropsychiatric disorders, brain injuries, vascular diseases, and cancers. Radiolabeled compounds for imaging of microtubules or microtubules and other targets using positron-emission tomography (PET) are specifically disclosed.

  本公开涉及放射性标记化合物及其在诊断、监测和治疗各种退行性神经疾病、神经精神疾病、脑损伤、血管疾病和癌症中的用途方法。具体公开了用于通过正电子发射断层扫描（PET）成像微管或微管和其他靶标的放射性标记化合物。
• Radiosynthesis and Evaluation of [¹¹C]HD-800, a High Affinity Brain Penetrant PET Tracer for Imaging Microtubules
  作者：Kiran Kumar Solingapuram Sai、Jaya Prabhakaran、Gayathri Ramanathan、Stephanie Rideout、Christopher Whitlow、Akiva Mintz、J. John Mann、J. S. Dileep Kumar

  DOI：10.1021/acsmedchemlett.8b00060

  日期：2018.5.10

  Microtubules (MTs) are highly abundant throughout the cytoskeleton, and their dysfunction is implicated in the pathogenesis of malignancies, various neurodegenerative disorders, and brain injuries. Validated radiotracers reported so far for MTs are [C-11]paclitaxel, [F-18]fluoropaclitaxel, and [C-11]docetaxel; however, they are well-characterized substrates of efflux transporters and consequently have poor uptake into the brain due to minimal blood brain barrier (BBB) penetration. PET imaging of MT expression requires radiolabeled BBB penetrating MT ligands, and it may offer a direct and more sensitive approach for early diagnosis, monitoring disease progression, and treatment effects in brain diseases and assessing the clinical potential of targeted therapeutics and treatments. We have identified N-(4-methoxyphenyl)-N-5dimethylfuro[2,3-d]pyrimidin-4-amine (HD-800) as a high affinity and selective colchicine site tubuline inhibitor amenable to radiolabel with C-11, a positron emitting isotope. HD-800 and desmethyl-HD-800 were synthesized in one step with 75% and 80% yields respectively from commercial synthons. The radiosynthesis of [C-11]HD-800 was achieved in 45 5% yield at EOS. Ex vivo biodistribution binding data of [C-11]HD-800 indicate that the radioligand penetrated the BBB and it was retained in brain with 75% specific binding. Apart from the brain, specific binding was observed in muscle (55%), heart (50%), lungs (43%), blood (37%), and pancreas (30%). MicroPET imaging in mice showed excellent binding in brain that was blocked by preadministration of unlabeled HD-800 and a colchicine site binding MT ligand MPC-6827. The above results indicate that [C-11]HD-800 may be a suitable PET ligand for the in vivo quantification of MT inside and outside the brain.
• RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20200290976A1

  公开（公告）日：2020-09-17

  The present disclosure relates to radiolabeled compounds and methods of uses for diagnosis, monitoring, and treatment of various degenerative neurological disorders, neuropsychiatric disorders, brain injuries, vascular diseases, and cancers. Radiolabled compounds for imaging of microtubules or microtubules and other targets using positron-emission tomography (PET) are specifically disclosed.
• Scaffold-hopping identifies furano[2,3-d]pyrimidine amides as potent Notum inhibitors
  作者：Benjamin N. Atkinson、David Steadman、William Mahy、Yuguang Zhao、James Sipthorp、Elliott D. Bayle、Fredrik Svensson、George Papageorgiou、Fiona Jeganathan、Sarah Frew、Amy Monaghan、Magda Bictash、E. Yvonne Jones、Paul V. Fish

  DOI：10.1016/j.bmcl.2019.126751

  日期：2020.2

  The carboxylesterase Notum is a key negative regulator of the Wnt signaling pathway by mediating the depalmitoleoylation of Wnt proteins. Our objective was to discover potent small molecule inhibitors of Notum suitable for exploring the regulation of Wnt signaling in the central nervous system. Scaffold-hopping from thienopyrimidine acids 1 and 2, supported by X-ray structure determination, identified 3-methylimidazolin-4-one amides 20-24 as potent inhibitors of Notum with activity across three orthogonal assay formats (biochemical, extra-cellular, occupancy). A preferred example 24 demonstrated good stability in mouse microsomes and plasma, and cell permeability in the MDCK-MDR1 assay albeit with modest P-gp mediated efflux. Pharmacokinetic studies with 24 were performed in vivo in mouse with single oral administration of 24 showing good plasma exposure and reasonable CNS penetration. We propose that 24 is a new chemical tool suitable for cellular studies to explore the fundamental biology of Notum.
• Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold
  作者：Ailing Zhao、Xin Gao、Yuanxiang Wang、Jing Ai、Ying Wang、Yi Chen、Meiyu Geng、Ao Zhang

  DOI：10.1016/j.bmc.2011.05.038

  日期：2011.7

  A series of thieno[2,3-d]pyrimidines and furo[2,3-d] pyrimidines were synthesized and evaluated for the c-Met inhibition. Thieno[2,3-d]pyrimidine 6b stood out as the most potent showing an IC(50) of 35.7 nM. This compound displayed high inhibitory effect on cell proliferation in BaF3-TPR-Met cells and showed high selectivity for c-Met family against other 14 tested kinases. However, compound 6b was found ineffective in the c-Met-dependent U-87MG human gliobastoma xenograft model that may be relevant to its poor PK profile. (C) 2011 Elsevier Ltd. All rights